Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Non-Current Assets (2022 - 2025)

Axsome Therapeutics' Non-Current Assets history spans 4 years, with the latest figure at $100.8 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 20.84% year-over-year to $100.8 million; the TTM value through Dec 2025 reached $409.9 million, up 21.92%, while the annual FY2025 figure was $100.8 million, 20.84% up from the prior year.
  • Non-Current Assets for Q4 2025 was $100.8 million at Axsome Therapeutics, down from $103.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $103.9 million in Q3 2025 and bottomed at $1.7 million in Q1 2022.
  • The 4-year median for Non-Current Assets is $85.5 million (2022), against an average of $84.2 million.
  • The largest annual shift saw Non-Current Assets soared 4796.74% in 2023 before it fell 7.58% in 2024.
  • A 4-year view of Non-Current Assets shows it stood at $85.8 million in 2022, then decreased by 2.17% to $84.0 million in 2023, then dropped by 0.64% to $83.4 million in 2024, then rose by 20.84% to $100.8 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Non-Current Assets are $100.8 million (Q4 2025), $103.9 million (Q3 2025), and $103.2 million (Q2 2025).